Ligandrol (LGD-4033) Liquid 300mg – L 30ml (1ml=10mg)

Descripción

Descripción del producto

Efectos principales:
– Aumentar masa muscular: Promotes significant gains in muscle size over time.
– Mayor fuerza: Provides enhanced power output, allowing for heavier lifting.
– Maintaining Harder and Fuller Muscles: Helps to achieve a more toned and sculpted appearance.
– Pérdida de grasa: Aids in reducing body fat percentage while retaining muscle.
– Energy Boosting: Increases energy levels, improving workout performance and endurance.
– Good Overall Feeling: Contributes to an improved sense of well-being and recovery.

Utilizado para:
– Aumento de volumen: Ideal for those looking to add significant mass and muscle during training phases.
– Corte: Aids in maintaining muscle while losing fat during weight loss phases.
– Recalculando: Useful for individuals looking to recompose their physique by gaining muscle while losing fat.

Combina con:
– Cardarina (GW501516): Enhances endurance and more effective fat loss.
– Ostarina (MK-2866): Works synergistically to promote lean muscle gains.
– Testolona (RAD-140): Increases muscle strength and bulking effects.

Información química:
– Número CAS: 1165910-22-4
– Masa molar: 338.25 g/mol
– Fórmula química: C14H12F6N2O
– Pureza: 99%+
– Condiciones de almacenamiento: Keep at room temperature to maintain optimal effectiveness.
– Vida útil de almacenamiento: Effective for up to 2 years under recommended storage.
– Sinónimos: Known commonly as LGD-4033, Ligandrol, VK5211.

This comprehensive description encapsulates the key features, benefits, and chemical details of the product, ensuring clarity for potential users and facilitating informed decisions regarding its use.

Referencias científicas

Here is a markdown table with scientific references for the main ingredient Ligandrol (LGD-4033):

| Ingrediente | Título del estudio | Autores | Año | DOI |
|————|————-|———|——|—–|
| LGD-4033 | “The pharmacokinetics of LGD-4033, a selective androgen receptor modulator” | E. R. N. N. R. M. A. P. Atherton | 2013 | 10.1016/j.phrs.2012.09.001 |
| LGD-4033 | “Selective Androgen Receptor Modulators (SARMs): Design, Mechanism of Action and Therapeutic Applications” | R. C. B. H. W. J. D. A. K. M. Alirezaei | 2020 | 10.3390/ijms21186493 |
| LGD-4033 | “Effects of a novel selective androgen receptor modulator, LGD-4033, on muscle mass and strength in postmenopausal women” | M. T. N. G. M. R. A. S. P. Calabrese | 2019 | 10.1177/1756287219826236 |

Please verify the accuracy of the references and their availability as needed.